安罗替尼二线治疗广泛期小细胞肺癌的临床疗效

林建光; 陈平; 解方为; 蔡忠福; 许天文

doi:10.3971/j.issn.1000-8578.2020.20.0369

安罗替尼二线治疗广泛期小细胞肺癌的临床疗效

Clinical Efficacy of Anlotinib as Second-line Treatment on Patients with Extensive Small Cell Lung Cancer

摘要

摘要:
目的观察分析安罗替尼二线治疗广泛期小细胞肺癌（SCLC）临床疗效及不良反应。
方法回顾性分析30例广泛期SCLC患者的临床资料，上述患者一线化疗失败后拒绝二线化疗，自愿选择口服安罗替尼靶向抗肿瘤治疗，每两周期进行一次疗效评价，观察安罗替尼的不良反应。
结果 30例患者中完全缓解（CR）0例，部分缓解（PR）5例、疾病稳定（SD）17例、疾病进展（PD）8例。客观缓解率（ORR）为16.7%，疾病控制率（DCR）为73.3%，无进展生存期（PFS）为4.2月，总生存期（OS）为8.6月。最常见不良反应为疲劳乏力、高血压、厌食、体重减轻等，3/4级不良反应发生率为16.7%。
结论安罗替尼二线治疗广泛期SCLC疗效较好，且大部分患者能够耐受不良反应。

Abstract:
Objective To observe and analyze the clinical efficacy and adverse reaction of anlotinib as the second-line treatment on extensive small cell lung cancer.
Methods We retrospectively analyzed the clinical data of the 30 patients with extensive small cell lung cancer. After the failure of the first-line chemotherapy, these patients rejected the second-line chemotherapy and voluntarily opted for oral targeted antitumor therapy with anlotinib. We evaluated the efficacy every two cycles and observed the adverse reaction.
Results Among 30 patients, there was 0 case with CR, 5 cases with PR, 17 cases with SD and 8 cases with PD. ORR was 16.7%, DCR was 73.3%, PFS was 4.2 months and OS was 8.6 months. The most common adverse reaction was fatigue, hypertension, anorexia, weight loss, etc. The incidence of grade 3/4 adverse reaction was 16.7%.
Conclusion Anlotinib as a second-line treatment for extensive small cell lung cancer has good curative effect and relatively low toxic side effects.

HTML全文

参考文献(18)

施引文献

资源附件(0)